Reviva Pharmaceuticals Holdings (RVPH) Interest Expenses (2023 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Interest Expenses of $6653.0 for Q1 2026, up 218.38% sequentially from -$5620.0 in Q4 2025, and down 42.75% YoY from $11620.0 in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Interest Expenses (2023 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Interest Expenses for 4 years, with the latest figure at $6653.0 in Q1 2026.
- Quarterly Interest Expenses fell 42.75% year-over-year to $6653.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8435.0 (down 73.38% YoY) and the FY2025 annual result came in at $35.3 million, up 12.19% from the prior year.
- Interest Expenses climbed to $6653.0 in Q1 2026 per RVPH's latest filing, from -$5620.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $314468.0 in Q2 2023 and troughed at -$5620.0 in Q4 2025.
- A 4-year average of $59891.8 and a median of $7655.0 in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses jumped 139.71% in 2024, then slumped 219.3% in 2025.
- Over 4 years, Interest Expenses stood at $10208.0 in 2023, then tumbled by 53.85% to $4711.0 in 2024, then plunged by 219.3% to -$5620.0 in 2025, then soared by 218.38% to $6653.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $6653.0, -$5620.0, and $2605.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | 2,935.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,935.00 |
| Jun 30, 2026 | 2,935.00 |
| Mar 31, 2026 | 6,653.00 |
| Mar 31, 2026 | 6,653.00 |
| Dec 31, 2025 | -5,620.00 |
| Dec 31, 2025 | -5,620.00 |
| Sep 30, 2025 | 2,605.00 |
| Sep 30, 2025 | 2,605.00 |
| Jun 30, 2025 | 4,797.00 |
| Jun 30, 2025 | 4,797.00 |
| Mar 31, 2025 | 11,620.00 |
| Mar 31, 2025 | 11,620.00 |
| Dec 31, 2024 | 4,711.00 |
| Dec 31, 2024 | 4,711.00 |
| Sep 30, 2024 | 83,525.00 |
| Sep 30, 2024 | 83,525.00 |
| Jun 30, 2024 | 5,153.00 |
| Jun 30, 2024 | 5,153.00 |
| Mar 31, 2024 | 18,350.00 |
| Mar 31, 2024 | 18,350.00 |